Scribe Therapeutics
6 articles with Scribe Therapeutics
-
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
5/2/2022
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced Biogen Inc. (Nasdaq:BIIB) has exercised an option for an additional disease target in gene therapy as part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based medicines.
-
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
4/1/2022
Scribe Therapeutics Inc. today announced its participation in the Goldman Sachs The New Guard: Privates Leading The Disruption In Healthcare conference.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
April springs up with showers of cash for these life sciences companies.
-
Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
3/31/2021
Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.